These findings could pave the way for the development of new targeted therapeutic strategies in the treatment of papillary thyroid carcinomas and point to ALK inhibitors as promising agents that merit rapid evaluation. The gene discussed is ALK; the disease is thyroid gland papillary carcinoma.